Plasma sCD14 as a biomarker to predict pulmonary exacerbations in cystic fibrosis.
<h4>Background</h4>One in four cystic fibrosis (CF) patients diagnosed with a pulmonary exacerbation will not recover their baseline lung function despite standard treatment. This highlights the importance of preventing such events. Clinical decision-making can be improved through a simp...
Saved in:
| Main Authors: | Bradley S Quon, David A Ngan, Pearce G Wilcox, S F Paul Man, Don D Sin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0089341&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A new Era of Personalized Medicine for Cystic Fibrosis – at Last!
by: Bradley S Quon, et al.
Published: (2015-01-01) -
Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations.
by: Ashutosh Sharma, et al.
Published: (2017-01-01) -
Optic Disc Swelling and Vision Loss in a Patient with Cystic Fibrosis and Diabetes
by: Ioulia Iosfina, et al.
Published: (2013-01-01) -
Evaluation of Copeptin during Pulmonary Exacerbation in Cystic Fibrosis
by: I. Wojsyk-Banaszak, et al.
Published: (2019-01-01) -
Study the alternative immunological parameters of immune cells (sCD14 and sCD163) in patients with chronic viral hepatitis B and C without treatment
by: Zahraa Al-Tamimi, et al.
Published: (2024-09-01)